CASC3 and Miyoshi myopathy: In 2013, Agyin et al. synthesized several permanently linked BP-conjugated proteasome inhibitors, including Btz, and demonstrated that these conjugates killed MM cells in vitro at a similar dose range as their non-bone targeted counterparts [10].